Seladelpar Achieves Primary, Secondary Endpoints in Phase 3

Results from RESPONSE show seladelpar may improve measures of disease activity and reduce symptom burden in patients with PBC.

Related Keywords

Toronto , Ontario , Canada , Gideon Hirschfield , Terry Horner , Drug Administration , Regulatory Agency , Foundation Gideon Hirschfield , European Medicines Agency , Toronto Centre For Liver Disease , Autoimmune Liver Disease Research , Bay Therapeutics , Terry Horner Chair , Toronto Centre , Seladelpar Achieves High Statistical Significance , Key Secondary Endpoints , Primary Biliary , Cymabay Initiates , Randomized Study , Primary Biliary Cholangitis , Incomplete Control , Phase 3 , Trial , Seladelpar , Alkaline Phosphatase , Alp , Cpbc ,